Brainsway

BWAY

Market cap $633M

Growing payer acceptance of nurse practitioner administration of Deep TMS is expected to expand access to non‑drug mental health treatments Growing payer acceptance of nurse practitioner administration of Deep TMS is expected to expand access to non‑drug mental health treatments

Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Brainsway (BWAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Wednesday, April 15, 2026.

AA, BWAY, FIVE, REFI and BWXT have been added to the Zacks Rank #1 (Strong Buy) List on April 13, 2026.

Brainsway Ltd. Sponsored ADR (BWAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

CDNL, BWAY and CENX are three stocks defying market weakness, with strong price momentum amid geopolitical turmoil.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Brainsway (BWAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

BrainsWay has delivered strong revenue growth, expanding its leasing model and recurring revenue base. BWAY reported 27% annual revenue growth, 75.4% gross margin, and issued 2026 guidance for $66–68M revenue and $12–14M adjusted EBITDA. The leasing model drives high-margin, stable recurring revenue with 93% customer retention and $70M in remaining performance obligations.

BrainsWay's investment is part of its ongoing strategy to partner with leading U.S. mental health providers to increase access to care BrainsWay's investment is part of its ongoing strategy to partner with leading U.S. mental health providers to increase access to care